The role of tumor microenvironment and immune response in colorectal cancer development and prognosis

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00843989%3A_____%2F22%3AE0109659" target="_blank" >RIV/00843989:_____/22:E0109659 - isvavai.cz</a>

Výsledek na webu

<a href="https://www.por-journal.com/articles/10.3389/pore.2022.1610502/full" target="_blank" >https://www.por-journal.com/articles/10.3389/pore.2022.1610502/full</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3389/pore.2022.1610502" target="_blank" >10.3389/pore.2022.1610502</a>

Jazyk výsledku

angličtina

Název v původním jazyce

The role of tumor microenvironment and immune response in colorectal cancer development and prognosis

Popis výsledku v původním jazyce

Colorectal cancer (CRC) is one of the most common cancers worldwide. The patient’s prognosis largely depends on the tumor stage at diagnosis. The pathological TNM Classification of Malignant Tumors (pTNM) staging of surgically resected cancers represents the main prognostic factor and guidance for decision-making in CRC patients. However, this approach alone is insufficient as a prognostic predictor because clinical outcomes in patients at the same histological tumor stage can still differ. Recently, significant progress in the treatment of CRC has been made due to improvements in both chemotherapy and surgical management. Immunotherapy-based approaches are one of the most rapidly developing areas of tumor therapy. This review summarizes the current knowledge about the tumor microenvironment (TME), immune response and its interactions with CRC development, immunotherapy and prognosis.

Název v anglickém jazyce

The role of tumor microenvironment and immune response in colorectal cancer development and prognosis

Popis výsledku anglicky

Colorectal cancer (CRC) is one of the most common cancers worldwide. The patient’s prognosis largely depends on the tumor stage at diagnosis. The pathological TNM Classification of Malignant Tumors (pTNM) staging of surgically resected cancers represents the main prognostic factor and guidance for decision-making in CRC patients. However, this approach alone is insufficient as a prognostic predictor because clinical outcomes in patients at the same histological tumor stage can still differ. Recently, significant progress in the treatment of CRC has been made due to improvements in both chemotherapy and surgical management. Immunotherapy-based approaches are one of the most rapidly developing areas of tumor therapy. This review summarizes the current knowledge about the tumor microenvironment (TME), immune response and its interactions with CRC development, immunotherapy and prognosis.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30102 - Immunology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2022

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Pathology & oncology research

ISSN

1532-2807

e-ISSN

1532-2807

Svazek periodika

28

Číslo periodika v rámci svazku

article 1610502

Stát vydavatele periodika

CH - Švýcarská konfederace

Počet stran výsledku

12

Strana od-do

1-12

Kód UT WoS článku

000872915300001

EID výsledku v databázi Scopus

2-s2.0-85135522745